XTalks

NOVEMBER 3, 2022

Eli Lilly is finding itself in an enviable position with its newly launched diabetes injection Mounjaro (tirzepatide) and blockbuster diabetes med Trulicity due to temporary shortages of competitor Novo Nordisk’s diabetes drug Ozempic (semaglutide). Lilly reported its stellar earnings in a release this week.

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

APRIL 18, 2024

This test, which is being co-developed with Eli Lilly, has the potential to facilitate earlier and more accurate detection of the disease. However, Roche has several CSF tests on the market, which include assays in the company’s Elecsys line that are used in conjunction with PET in the diagnosis and monitoring of the disease.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody 130

Antibody DNA Development Vaccination 130

pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

Trials 52

Trials Sales Marketing FDA Approval 52

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. Related: Eli Lilly’s Type 2 Diabetes Shot Tirzepatide Emerges Winner Against Semaglutide.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

MAY 4, 2021

Raises Full-Year 2021 Guidance (3) for Revenues to a Range of $70.5 Billion and Adjusted Diluted EPS (2) to a Range of $3.55 Now Anticipates Revenues of Approximately $26 Billion for BNT162b2, Reflecting 1.6 Billion Doses Expected to be Delivered in 2021 Under Signed Contracts as of Mid-April 2021. Viatris) (4). EXECUTIVE COMMENTARY.

Vaccination 40

Vaccination Vaccine Production Sales 40